Clopidogrel Viatris (previously Clopidogrel Taw Pharma) यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

Tobi Podhaler यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

tobi podhaler

viatris healthcare limited - tobramysiini - cystic fibrosis; respiratory tract infections - systeemiset bakteerilääkkeet, - tobi podhaler on tarkoitettu pseudomonas aeruginosan aiheuttaman kroonisen keuhkotulehduksen suppressoivaan hoitoon aikuisilla ja 6-vuotiailla ja sitä vanhemmilla lapsilla, joilla on kystinen fibroosi. katso kohdat 4. 4 ja 5. 1 tietoja eri ikäryhmissä. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.